4SCAR-276

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug Name4SCAR-276

Drug Alias Name4SCAR-CD276-modified T cellsCD276-specific 4th Generation CART4SCAR-276

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived +[4]

Mechanisms of ActionCD276 antigen inhibitors

TargetsCD276 antigen

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaPending

Originator CompaniesShenzhen Geno-Immune Medical Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesShenzhen Geno-Immune Medical Institute

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A